Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart
about
Calsequestrin 2 and arrhythmiasProteomic profiling of the dystrophin-deficient mdx phenocopy of dystrophinopathy-associated cardiomyopathyThe role of oxidative stress in skeletal muscle injury and regeneration: focus on antioxidant enzymesFunctional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular DystrophySpeckle tracking analysis of the left ventricular anterior wall shows significantly decreased relative radial strain patterns in dystrophin deficient mice after 9 months of ageGlucocorticoid-treated mice are an inappropriate positive control for long-term preclinical studies in the mdx mouseNon-invasive MRI and spectroscopy of mdx mice reveal temporal changes in dystrophic muscle imaging and in energy deficitsPrevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice.Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse.Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic miceArginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy.Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophyMimicking Cardiac Fibrosis in a Dish: Fibroblast Density Rather than Collagen Density Weakens Cardiomyocyte FunctionSkeletal muscle NADPH oxidase is increased and triggers stretch-induced damage in the mdx mouse.Proteomic Profiling of the Dystrophin-Deficient MDX Heart Reveals Drastically Altered Levels of Key Metabolic and Contractile Proteins.Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.Impaired functional communication between the L-type calcium channel and mitochondria contributes to metabolic inhibition in the mdx heart.Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures.An evaluation of transmitral and pulmonary venous Doppler indices for assessing murine left ventricular diastolic function.Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.Diapocynin, a dimer of the NADPH oxidase inhibitor apocynin, reduces ROS production and prevents force loss in eccentrically contracting dystrophic muscleThe proton pump inhibitor lansoprazole improves the skeletal phenotype in dystrophin deficient mdx miceCardiac function in muscular dystrophy associates with abdominal muscle pathology.Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J miceThe NOX toolbox: validating the role of NADPH oxidases in physiology and disease.Deletion of Galgt2 (B4Galnt2) reduces muscle growth in response to acute injury and increases muscle inflammation and pathology in dystrophin-deficient miceCrosstalk between RyR2 oxidation and phosphorylation contributes to cardiac dysfunction in mice with Duchenne muscular dystrophy.Effect of genetic background on the dystrophic phenotype in mdx mice.Vascular-targeted therapies for Duchenne muscular dystrophyA potential role for insulin resistance in experimental pulmonary hypertensionWasting mechanisms in muscular dystrophy.Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetesIncreased collagen cross-linking is a signature of dystrophin-deficient muscle.Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with Duchenne muscular dystrophy.Evaluation of the therapeutic utility of phosphodiesterase 5A inhibition in the mdx mouse model of duchenne muscular dystrophy.Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy.Oxidative stress in muscular dystrophy: from generic evidence to specific sources and targets.What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?Transcriptional assessment by microarray analysis and large-scale meta-analysis of the metabolic capacity of cardiac and skeletal muscle tissues to cope with reduced nutrient availability in Gilthead Sea Bream (Sparus aurata L.).Drug Discovery of Therapies for Duchenne Muscular Dystrophy.
P2860
Q24300626-0E21EE70-B804-44CF-A1FF-4C3ADEDFDACAQ27006945-AC0574E4-A270-45AF-8675-BF627D639C82Q28076877-C20459B9-1475-46E6-8DE9-7094054FB66EQ28474542-66A64109-35EE-46E3-9533-7E3F38183F46Q28480442-D22AC99C-ABF6-4EB1-8909-5DDFF181CFBCQ28482090-E30DB433-E5DD-4C85-9733-7B9AF3EA3FE0Q28544896-8B58A52C-2CDF-4875-B95A-13925AA0D21EQ30626615-28125949-A683-4C1D-99BD-11B9A7B0E356Q33529003-40CAF577-6F68-4E59-B00D-9E556DB7F2C3Q33531816-B5804FBC-682D-4AD1-98E5-E1BD57729089Q33588636-388CD091-FD35-4A5F-95FD-3B0CF55B60A6Q33649312-4A52EE7B-F0DC-4900-A5C2-B5C2AF7A2A51Q33705089-A918F7D6-CC40-49A4-B418-8E2CB05729E3Q33781098-AD6353B4-6912-4DA1-BE5D-5C1181E9B08AQ33871052-C3FA2BC5-30E2-406F-955B-DC63E31AF290Q33901556-A6D8C913-00FE-4652-B5A3-6BC208C861E1Q33925699-AC7626C5-7023-48E2-866C-B6763265FFC3Q33975979-84F82E48-5EF6-4852-A643-47DCAD74CAB1Q34023329-E13E332A-C3BF-490C-A90D-2B069C5D1F82Q34103278-31683E31-EDB4-4330-B665-D30325D86A7DQ34444163-A21CA4F1-02AA-4DAC-BD9C-C55E8F74533FQ34812217-E3206D62-7A18-4A00-B619-998C46849DF4Q35660390-138FE413-D96D-481B-ABF9-D390B6738640Q35984257-DBC004EA-AAD5-4AE7-BA47-FB5FDA1AE3CDQ36060782-ECA94C71-FD33-4ACC-A7E8-80F540E39AA4Q36167600-010F08E0-2D65-4BDD-BF07-3BA8DF1F38ABQ36399838-0382D2B6-8EF9-4351-B732-808309B20D69Q36402584-969A82BC-FB3F-42FC-B65C-C0FC2AC6D44CQ36835180-05D48A7E-F3DD-4A2C-9FC6-99AC8218942CQ37104263-F7FF8CA6-5359-4D42-951E-4B4474F5B400Q37138490-496C8131-D3FC-430F-B846-7E8F02ED8564Q37270928-54B0BF15-4CA6-4C1A-A1BC-91EF38908C17Q37345809-45D18104-803D-41D7-8370-C714899398CDQ37864433-B7547029-CB0C-4A36-B87B-4B7D5096329DQ37893076-1951FDFA-4761-498E-B40A-6AED9A9F3C91Q38056065-5455C7CD-B630-47C8-8771-4FA3AA83C992Q38195206-AE219905-90EF-431E-8946-60EA68B76314Q38351283-D3D65708-78DC-475B-98EF-BB0AB7FE4EA0Q38478822-F6E4D992-0E48-4FA2-8EDB-AB3D044489BAQ38480698-190DF7B5-56DE-4025-B807-F55552577084
P2860
Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Dystrophin-deficient cardiomyo ...... tional parameters in the heart
@ast
Dystrophin-deficient cardiomyo ...... tional parameters in the heart
@en
type
label
Dystrophin-deficient cardiomyo ...... tional parameters in the heart
@ast
Dystrophin-deficient cardiomyo ...... tional parameters in the heart
@en
prefLabel
Dystrophin-deficient cardiomyo ...... tional parameters in the heart
@ast
Dystrophin-deficient cardiomyo ...... tional parameters in the heart
@en
P2093
P2860
P1476
Dystrophin-deficient cardiomyo ...... tional parameters in the heart
@en
P2093
Christopher F Spurney
Emidio E Pistilli
Eric P Hoffman
Gerard R Martin
Susan Knoblach
P2860
P304
P356
10.1016/J.NMD.2008.03.008
P577
2008-04-25T00:00:00Z